Drug intelligence / Profile preview

PG286

Development stage: Preclinical
Lead developer: Alcon
Administration: Ophthalmic

Overview

PG286 is an investigational ophthalmic solution evaluated for its safety and ocular hypotensive efficacy. It has been studied in clinical trials as a topical treatment for lowering intraocular pressure, likely targeting conditions such as glaucoma or ocular hypertension. The drug has been compared to its individual components in clinical research, but detailed information about its mechanism of action, chemical class, or specific molecular target is not available from the provided sources[3].

Other names: PG286PG-286PG 286

Beyond the preview

Go deeper on PG286.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PG286.

Explore the full profile